Persons with dispensed medicines; origin
Sex | Age | Origin | Medicine group (ATC) | Periods | Persons with medicines, relative (%) | Defined daily doses (DDD), relative (number per 1 000 persons) |
---|---|---|---|---|---|---|
Total male and female | Total age | Total | C Cardiovascular system | 2022* | 21.25 | 163,444 |
Total male and female | Total age | Total | C01 Cardiac therapy | 2022* | 2.53 | 5,148 |
Total male and female | Total age | Total | C01A Cardiac glycosides | 2022* | 0.45 | 657 |
Total male and female | Total age | Total | C01C Cardiac stimulants excl. glycosides | 2022* | 0.36 | 6 |
Total male and female | Total age | Total | C01D Vasodilators used in card. diseases | 2022* | 1.40 | 3,406 |
Total male and female | Total age | Total | C01E Other cardiac preparations | 2022* | 0.07 | 189 |
Total male and female | Total age | Total | C08D Sel.calcium ch.block.direct cardiac | 2022* | 0.64 | 1,407 |
Total male and female | Total age | Total | V09G Cardiovascular system | 2022* | 0.00 | 0 |
Total male and female | Total age | Origin: born in the Netherlands | C Cardiovascular system | 2022* | 21.99 | 169,417 |
Total male and female | Total age | Origin: born in the Netherlands | C01 Cardiac therapy | 2022* | 2.67 | 5,438 |
Total male and female | Total age | Origin: born in the Netherlands | C01A Cardiac glycosides | 2022* | 0.50 | 724 |
Total male and female | Total age | Origin: born in the Netherlands | C01C Cardiac stimulants excl. glycosides | 2022* | 0.40 | 7 |
Total male and female | Total age | Origin: born in the Netherlands | C01D Vasodilators used in card. diseases | 2022* | 1.44 | 3,536 |
Total male and female | Total age | Origin: born in the Netherlands | C01E Other cardiac preparations | 2022* | 0.07 | 191 |
Total male and female | Total age | Origin: born in the Netherlands | C08D Sel.calcium ch.block.direct cardiac | 2022* | 0.68 | 1,513 |
Total male and female | Total age | Origin: born in the Netherlands | V09G Cardiovascular system | 2022* | 0.00 | 0 |
Total male and female | Total age | Origin: born in NL, parents in NL | C Cardiovascular system | 2022* | 23.66 | 183,293 |
Total male and female | Total age | Origin: born in NL, parents in NL | C01 Cardiac therapy | 2022* | 2.85 | 5,880 |
Total male and female | Total age | Origin: born in NL, parents in NL | C01A Cardiac glycosides | 2022* | 0.54 | 788 |
Total male and female | Total age | Origin: born in NL, parents in NL | C01C Cardiac stimulants excl. glycosides | 2022* | 0.39 | 7 |
Total male and female | Total age | Origin: born in NL, parents in NL | C01D Vasodilators used in card. diseases | 2022* | 1.55 | 3,814 |
Total male and female | Total age | Origin: born in NL, parents in NL | C01E Other cardiac preparations | 2022* | 0.08 | 204 |
Total male and female | Total age | Origin: born in NL, parents in NL | C08D Sel.calcium ch.block.direct cardiac | 2022* | 0.73 | 1,637 |
Total male and female | Total age | Origin: born in NL, parents in NL | V09G Cardiovascular system | 2022* | 0.00 | 0 |
Total male and female | Total age | Origin: born in NL, parent(s) abroad | C Cardiovascular system | 2022* | 11.41 | 81,753 |
Total male and female | Total age | Origin: born in NL, parent(s) abroad | C01 Cardiac therapy | 2022* | 1.57 | 2,646 |
Total male and female | Total age | Origin: born in NL, parent(s) abroad | C01A Cardiac glycosides | 2022* | 0.22 | 320 |
Total male and female | Total age | Origin: born in NL, parent(s) abroad | C01C Cardiac stimulants excl. glycosides | 2022* | 0.46 | 6 |
Total male and female | Total age | Origin: born in NL, parent(s) abroad | C01D Vasodilators used in card. diseases | 2022* | 0.73 | 1,778 |
Total male and female | Total age | Origin: born in NL, parent(s) abroad | C01E Other cardiac preparations | 2022* | 0.04 | 105 |
Total male and female | Total age | Origin: born in NL, parent(s) abroad | C08D Sel.calcium ch.block.direct cardiac | 2022* | 0.34 | 725 |
Total male and female | Total age | Origin: born in NL, parent(s) abroad | V09G Cardiovascular system | 2022* | 0.00 | 0 |
Total male and female | Total age | Origin: born in NL, 1 parent born in NL | C Cardiovascular system | 2022* | 15.87 | 119,894 |
Total male and female | Total age | Origin: born in NL, 1 parent born in NL | C01 Cardiac therapy | 2022* | 2.23 | 4,154 |
Total male and female | Total age | Origin: born in NL, 1 parent born in NL | C01A Cardiac glycosides | 2022* | 0.36 | 518 |
Total male and female | Total age | Origin: born in NL, 1 parent born in NL | C01C Cardiac stimulants excl. glycosides | 2022* | 0.52 | 7 |
Total male and female | Total age | Origin: born in NL, 1 parent born in NL | C01D Vasodilators used in card. diseases | 2022* | 1.10 | 2,788 |
Total male and female | Total age | Origin: born in NL, 1 parent born in NL | C01E Other cardiac preparations | 2022* | 0.06 | 150 |
Total male and female | Total age | Origin: born in NL, 1 parent born in NL | C08D Sel.calcium ch.block.direct cardiac | 2022* | 0.49 | 1,086 |
Total male and female | Total age | Origin: born in NL, 1 parent born in NL | V09G Cardiovascular system | 2022* | 0.00 | 0 |
Total male and female | Total age | Origin: born in NL,2 parents born abroad | C Cardiovascular system | 2022* | 5.99 | 35,359 |
Total male and female | Total age | Origin: born in NL,2 parents born abroad | C01 Cardiac therapy | 2022* | 0.77 | 812 |
Total male and female | Total age | Origin: born in NL,2 parents born abroad | C01A Cardiac glycosides | 2022* | 0.05 | 79 |
Total male and female | Total age | Origin: born in NL,2 parents born abroad | C01C Cardiac stimulants excl. glycosides | 2022* | 0.38 | 5 |
Total male and female | Total age | Origin: born in NL,2 parents born abroad | C01D Vasodilators used in card. diseases | 2022* | 0.28 | 551 |
Total male and female | Total age | Origin: born in NL,2 parents born abroad | C01E Other cardiac preparations | 2022* | 0.02 | 50 |
Total male and female | Total age | Origin: born in NL,2 parents born abroad | C08D Sel.calcium ch.block.direct cardiac | 2022* | 0.15 | 286 |
Total male and female | Total age | Origin: born in NL,2 parents born abroad | V09G Cardiovascular system | 2022* | 0.00 | 0 |
Total male and female | Total age | Origin: born abroad | C Cardiovascular system | 2022* | 17.40 | 132,317 |
Total male and female | Total age | Origin: born abroad | C01 Cardiac therapy | 2022* | 1.78 | 3,633 |
Total male and female | Total age | Origin: born abroad | C01A Cardiac glycosides | 2022* | 0.22 | 308 |
Total male and female | Total age | Origin: born abroad | C01C Cardiac stimulants excl. glycosides | 2022* | 0.19 | 3 |
Total male and female | Total age | Origin: born abroad | C01D Vasodilators used in card. diseases | 2022* | 1.22 | 2,727 |
Total male and female | Total age | Origin: born abroad | C01E Other cardiac preparations | 2022* | 0.07 | 178 |
Total male and female | Total age | Origin: born abroad | C08D Sel.calcium ch.block.direct cardiac | 2022* | 0.41 | 856 |
Total male and female | Total age | Origin: born abroad | V09G Cardiovascular system | 2022* | 0.00 | 0 |
Total male and female | Total age | Origin country: The Netherlands | C Cardiovascular system | 2022* | 23.66 | 183,293 |
Total male and female | Total age | Origin country: The Netherlands | C01 Cardiac therapy | 2022* | 2.85 | 5,880 |
Total male and female | Total age | Origin country: The Netherlands | C01A Cardiac glycosides | 2022* | 0.54 | 788 |
Total male and female | Total age | Origin country: The Netherlands | C01C Cardiac stimulants excl. glycosides | 2022* | 0.39 | 7 |
Total male and female | Total age | Origin country: The Netherlands | C01D Vasodilators used in card. diseases | 2022* | 1.55 | 3,814 |
Total male and female | Total age | Origin country: The Netherlands | C01E Other cardiac preparations | 2022* | 0.08 | 204 |
Total male and female | Total age | Origin country: The Netherlands | C08D Sel.calcium ch.block.direct cardiac | 2022* | 0.73 | 1,637 |
Total male and female | Total age | Origin country: The Netherlands | V09G Cardiovascular system | 2022* | 0.00 | 0 |
Total male and female | Total age | Origin country: abroad | C Cardiovascular system | 2022* | 14.91 | 111,284 |
Total male and female | Total age | Origin country: abroad | C01 Cardiac therapy | 2022* | 1.70 | 3,222 |
Total male and female | Total age | Origin country: abroad | C01A Cardiac glycosides | 2022* | 0.22 | 313 |
Total male and female | Total age | Origin country: abroad | C01C Cardiac stimulants excl. glycosides | 2022* | 0.30 | 4 |
Total male and female | Total age | Origin country: abroad | C01D Vasodilators used in card. diseases | 2022* | 1.02 | 2,332 |
Total male and female | Total age | Origin country: abroad | C01E Other cardiac preparations | 2022* | 0.06 | 148 |
Total male and female | Total age | Origin country: abroad | C08D Sel.calcium ch.block.direct cardiac | 2022* | 0.38 | 801 |
Total male and female | Total age | Origin country: abroad | V09G Cardiovascular system | 2022* | 0.00 | 0 |
Total male and female | Total age | Origin country: Europe (excl. NL) | C Cardiovascular system | 2022* | 14.42 | 109,834 |
Total male and female | Total age | Origin country: Europe (excl. NL) | C01 Cardiac therapy | 2022* | 1.86 | 3,822 |
Total male and female | Total age | Origin country: Europe (excl. NL) | C01A Cardiac glycosides | 2022* | 0.35 | 487 |
Total male and female | Total age | Origin country: Europe (excl. NL) | C01C Cardiac stimulants excl. glycosides | 2022* | 0.27 | 4 |
Total male and female | Total age | Origin country: Europe (excl. NL) | C01D Vasodilators used in card. diseases | 2022* | 1.04 | 2,592 |
Total male and female | Total age | Origin country: Europe (excl. NL) | C01E Other cardiac preparations | 2022* | 0.05 | 143 |
Total male and female | Total age | Origin country: Europe (excl. NL) | C08D Sel.calcium ch.block.direct cardiac | 2022* | 0.42 | 921 |
Total male and female | Total age | Origin country: Europe (excl. NL) | V09G Cardiovascular system | 2022* | 0.00 | 0 |
Total male and female | Total age | Origin country: outside Europe | C Cardiovascular system | 2022* | 15.17 | 112,046 |
Total male and female | Total age | Origin country: outside Europe | C01 Cardiac therapy | 2022* | 1.61 | 2,908 |
Total male and female | Total age | Origin country: outside Europe | C01A Cardiac glycosides | 2022* | 0.16 | 221 |
Total male and female | Total age | Origin country: outside Europe | C01C Cardiac stimulants excl. glycosides | 2022* | 0.32 | 4 |
Total male and female | Total age | Origin country: outside Europe | C01D Vasodilators used in card. diseases | 2022* | 1.00 | 2,196 |
Total male and female | Total age | Origin country: outside Europe | C01E Other cardiac preparations | 2022* | 0.06 | 151 |
Total male and female | Total age | Origin country: outside Europe | C08D Sel.calcium ch.block.direct cardiac | 2022* | 0.35 | 738 |
Total male and female | Total age | Origin country: outside Europe | V09G Cardiovascular system | 2022* | 0.00 | 0 |
Total male and female | Total age | Origin country: Morocco | C Cardiovascular system | 2022* | 12.61 | 87,853 |
Total male and female | Total age | Origin country: Morocco | C01 Cardiac therapy | 2022* | 1.27 | 2,181 |
Total male and female | Total age | Origin country: Morocco | C01A Cardiac glycosides | 2022* | 0.14 | 207 |
Total male and female | Total age | Origin country: Morocco | C01C Cardiac stimulants excl. glycosides | 2022* | 0.33 | 4 |
Total male and female | Total age | Origin country: Morocco | C01D Vasodilators used in card. diseases | 2022* | 0.69 | 1,579 |
Total male and female | Total age | Origin country: Morocco | C01E Other cardiac preparations | 2022* | 0.04 | 92 |
Total male and female | Total age | Origin country: Morocco | C08D Sel.calcium ch.block.direct cardiac | 2022* | 0.23 | 444 |
Total male and female | Total age | Origin country: Morocco | V09G Cardiovascular system | 2022* | 0.00 | 0 |
Total male and female | Total age | Origin country: Turkey | C Cardiovascular system | 2022* | 16.26 | 125,479 |
Total male and female | Total age | Origin country: Turkey | C01 Cardiac therapy | 2022* | 1.89 | 3,973 |
Total male and female | Total age | Origin country: Turkey | C01A Cardiac glycosides | 2022* | 0.18 | 258 |
Total male and female | Total age | Origin country: Turkey | C01C Cardiac stimulants excl. glycosides | 2022* | 0.19 | 3 |
Source: CBS. |
Dataset is not available.
This table contains figures on the absolute number of persons to whom in the year concerned medicines were dispensed for which the costs are reimbursed under the statutory basic medical insurance. Also, the number of dispensed defined daily doses (DDDs) are presented. The figures are also expressed as a percentage of the total population in the category concerned. The population includes everybody registered in the Basic Registration of Persons (BRP) and living in the Netherlands at some point in the year concerned. Until 2010 the figures also included medicines dispensed to persons registered in the BRP, but no longer resident in the Netherlands.
Medicines provided to persons in hospitals and nursing homes are not included; medicines provided in residential homes for the elderly are included.
Data are broken down by medicine group, origin, age and sex.
Data available from 2020.
Status of the figures:
Figures for 2022 are provisional.
Changes as of December 20, 2023:
- Provisional figures for 2022 have been added, provisional figures of 2020 and 2021 have been made definite.
- Textual change: the description of drug group Y (Not filled in) has been replaced by Z (Not applicable). However, the underlying resources have remained the same. This category is assigned to products that do not have an ATC code according to the WHO ATC classification system.
When will new figures be published?
New figures will be published in the last quarter of 2024.
Description topics
- Persons with medicines, relative
- Number of persons to whom medicines are dispensed in the year concerned that are reimbursed under the statutory basic medical insurance, expressed as a percentage of the total population of the category concerned registered in the Basic Registration of Persons (BRP) in that year.
- Defined daily doses (DDD), relative
- Defined Daily Dose (DDD) is de door de WHO vastgestelde gemiddelde dagelijkse dosis van een geneesmiddel, wanneer het geneesmiddel wordt ingezet voor de hoofdindicatie, bij een onderhoudsbehandeling voor volwassenen. Deze definitie maakt het mogelijk om het gebruik van verschillende toedieningsvormen en verschillende middelen met elkaar te vergelijken.
WHO: World Health Organisation, Wereldgezondheidsorganisatie